Assessing pregnancy risks of azole antifungals using a high throughput aromatase inhibition assay

Endocrine Research

Volumn 28, Issue 3, 2002, Pages 129-140

  Kragie, Laura ^a   Turner, Stephanie D ^b   Patten, Christopher J ^b   Crespi, Charles L ^b   Stresser, David M ^b  

^a Endocrine Health Foundation   (United States)

^b BD Biosciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 BENZYLIMIDAZOLE; ANTIFUNGAL AGENT; AROMATASE; BIFONAZOLE; CLOTRIMAZOLE; CYTOCHROME P450 ISOENZYME; ECONAZOLE; FLUCONAZOLE; FLUORESCEIN DERIVATIVE; ITRACONAZOLE; KETOCONAZOLE; METRONIDAZOLE; MICONAZOLE; PYRROLE DERIVATIVE; RECOMBINANT ENZYME; RONIDAZOLE; SULCONAZOLE; SULFAPHENAZOLE; TETRACONAZOLE; TIABENDAZOLE; TINIDAZOLE; UNCLASSIFIED DRUG; AROMATASE INHIBITOR; IMIDAZOLE DERIVATIVE;

ARTICLE; BIOASSAY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; DRUG TISSUE LEVEL; EMBRYOTOXICITY; ENZYME ACTIVITY; ENZYME CHEMISTRY; ENZYME INHIBITION; ENZYME KINETICS; ESTROGEN SYNTHESIS; FETOTOXICITY; FLUOROMETRY; HUMAN; IC 50; INTERMETHOD COMPARISON; NONHUMAN; PREGNANCY COMPLICATION; PRIORITY JOURNAL; REPRODUCTIVE TOXICITY; STRUCTURE ACTIVITY RELATION; TECHNIQUE; TERATOGENICITY; VALIDATION PROCESS; ANIMAL; BACULOVIRUS; COMPARATIVE STUDY; ENZYMOLOGY; FEMALE; INSECT; METABOLISM; MICROSOME; PLACENTA; PREGNANCY;

ANIMALS; ANTIFUNGAL AGENTS; AROMATASE INHIBITORS; BACULOVIRIDAE; FEMALE; HUMANS; IMIDAZOLES; INHIBITORY CONCENTRATION 50; INSECTS; MICROSOMES; PLACENTA; PREGNANCY;

EID: 0036443388     PISSN: 07435800     EISSN: None     Source Type: Journal    
DOI: 10.1081/ERC-120015045     Document Type: Article

References (42)

1. Kragie, L. Aromatase in primate pregnancy: A review. Endocrine Research 2002, 28 (3), 121-128.
2. Osawa, Y.; Higashiyama, T.; Toma, Y.; Yarborough, C. Diverse Function of aromatase and the N-Terminal sequence deleted form. J. Steroid Biochem. Mol. Biol. 1997, 61 (3-6), 117-126.
3. Simpson, E.R.; Mahendroo, M.S.; Means, G.D.; Kilgore, M.W.; Hinshelwood, M.M.; Graham-Lorence, S.; Amarneh, B.; Ito, Y.; Fisher, C.R.; Michael, M.D. et al. Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocr. Rev. 1994, 15 (3), 342-355.
4. Labrie, F. DHEA as physiological replacement therapy at menopause. J. Endocrinol. Invest. 1998, 21 (6), 399-401.
5. Adams, J.B. Control of secretion and the function of C19-Delta 5-steroids of the human adrenal gland. Mol. Cell. Endocrinol. 1985, 41 (1), 1-17.
6. Resko, J.A.; Roselli, C.E. Prenatal hormones organize sex differences of the neuroendocrine reproductive system: Observations on guinea pigs and nonhuman primates. Cell Mol. Neurobiol. 1997, 17 (6), 627-648.
7. Kao, Y.C.; Higashiyama, T.; Sun, X.; Okubo, T.; Yarborough, C.; Choi, I.; Osawa, Y.; Simmen, F.A.; Chen, S. Catalytic differences between porcine blastocyst and placental aromatase isozymes. Eur. J. Biochem. 2000, 267 (20), 6134-6139.
8. Albrecht, E.D.; Aberdeen, G.W.; Pepe, G.J. The role of estrogen in the maintenance of primate pregnancy. Am. J. Obstet. Gynecol. 2000, 182 (2), 432-438.
9. Nathanielsz, P.W.; Jenkins, S.L.; Tame, J.D.; Winter, J.A.; Guller, S.; Giussani, D.A. Local paracrine effects of estradiol are central to parturition in the Rhesus Monkey. Nat. Med. 1998, 4 (4), 456-459.
10. Mason, J.I.; Murry, B.A.; Olcott, M.; Sheets, J.J. Imidazole antimycotics: Inhibitors of steroid aromatase. Biochemical Pharmacology 1985, 34, 1087-1092.
11. Ayub, M.; Levell, M.J. Structure-activity relationships of the inhibition of human placental aromatase by imidazole drugs including ketoconazole. J. Steroid Biochem. 1988, 31 (1), 65-72.
12. Kragie, L.; Amri, H.; Gore, L.; Flockhart, D.; Papadopoulos, V. 1996 Cytochrome P450 aromatase: An in vitro screening tool for drug-steroid interactions. 10th International Congress of Endocrinology, Endocrine Society: San Francisco, CA, June 1996; pp. Program Abstract #P3-480 p. 874.
13. Stresser, D.M.; Turner, S.D.; McNamara, J.; Stocker, P.; Miller, V.P; Crespi, C.L.; Patten, C.J. A high-throughput screen to identify inhibitors of aromatase (CYP19). Anal. Biochem. 2000, 284 (2), 427-430.
14. Hakkola, J.; Pasanen, M.; Hukkanen, J.; Pelkonen, O.; Maenpaa, J.; Edwards, R.J.; Boobis, A.R.; Raunio, H. Expression of xenobiotic-metabolizing cytochrome P450 forms in human full-term placenta. Biochem. Pharmacol. 1996, 51 (4), 403-411.
15. Fromtling, R.A. Overview of medically important antifungal azole derivatives. Clin. Microbiol. Rev. 1988, 1 (2), 187-217.
16. Spectazole® package insert. In: Physicians Desk Reference. Medical Economics Company Inc.: Montvale, NJ, 2000.
17. Plempel, M. Pharmacokinetics of imidazole antimycotics. Postgrad. Med. J. 1979, 55 (647), 662-666.
18. 3H] econazole in man. Xenobiotica 1981, 11 (9), 595-608.
19. 14C] bifonazole in man. Arzneimittelforschung 1983, 33 (5), 745-750.
20. Lackner, T.E.; Clissold, S.P. Bifonazole. A review of its antimicrobial activity and therapeutic use in superficial mycoses. Drugs 1989, 38 (2), 204-225.
21. Lucker, P.W.; Beubler, E.; Kukovetz, W.R.; Ritter, W. Retention time and concentration in human skin of bifonazole and clotrimazole. Dermatologica 1984, 169 (1), 51-55.
22. Myclex-G® package insert. In: Physicians Desk Reference. Medical Economics Company Inc.: Montvale, NJ, 2000.
23. Heel, R.C.; Brogden, R.N.; Pakes, G.E.; Speight, T.M.; Avery, G.S. Miconazole: A preliminary review of its therapeutic efficacy in systemic fungal infections. Drugs 1980, 19 (1), 7-30.
24. Daneshmend, T.K. Systemic absorption of miconazole from the vagina. J. Antimicrob. Chemother. 1986, 18 (4), 507-511.
25. Beggs, W.H. Fungistatic activity of miconazole against candida albicans in relation to pH and concentration of nonprotonated drug. Mycoses 1989, 32 (5), 239-244.
26. Franz, T.J.; Lehman, P. Percutaneous absorption of sulconazole nitrate in humans. J. Pharm. Sci. 1988, 77 (6), 489-491.
27. Nizoral® package insert. In: Physicians Desk Reference. Medical Economics Company Inc.: Montvale, NJ, 2000.
28. Mikamo, H.; Kawazoe, K.; Sato, Y.; Izumi, K.; Ito, T.; Ito, K.; Tamaya, T. Penetration of Oral Fluconazole Into Gynecological Tissues. Antimicrob. Agents Chemother. 1999, 43 (1), 148-151.
29. Schramm, P.; Wildfeuer, A.; Sarnow, E. Determination of fluconazole concentrations in the prostatic and seminal vesicle fluid (Split Ejaculate). Mycoses 1994, 37 (11-12), 417-420.
30. Garcia-Hermoso, D.; Dromer, F; Improvisi, L.; Provost, F; Dupont, B. Fluconazole concentrations in saliva from AIDS patients with oropharyngeal candidosis refractory to treatment with fluconazole. Antimicrob. Agents Chemother. 1995, 39 (3), 656-660.
31. Rieder-Nelissen, C.M.; Hasse, J.; Yeates, R.A.; Sarnow, E. Fluconazole concentrations in pulmonary tissue and pericardial fluid. Infection 1997, 25 (3), 192-194.
32. Wenzl, T.G.; Schefels, J.; Hornchen, H.; Skopnik, H. Pharmacokinetics of oral fluconazole in premature infants. Eur. J. Pediatr. 1998, 157 (8), 661-662.
33. Monistat® package insert. In: Physicians Desk Reference. Medical Economics Company Inc.: Montvale, NJ, 1991.
34. Sasaki, J.; Yamamoto, T.; Okada, H. The synergistic abortive effect of anti-progestogen RU 38486 and aromatase inhibitors for pregnant rat. Nippon Sanka Fujinka Gakkai Zasshi 1989, 41 (2), 179-184.
35. Beltrame, D.; di Salle, E.; Giavini, E.; Gunnarsson, K.; Brughera, M. Reproductive toxicity of exemestane, an antitumoral aromatase inactivator, in rats and rabbits. Reprod. Toxicol. 2001, 15 (2), 195-213.
36. Pursley, T.J.; Blomquist, I.K.; Abraham, J.; Andersen, H.E; Bartley, J.A. Fluconazole-induced congenital anomalies in three infants. Clin. Infect. Dis. 1996, 22 (2), 336-340.
37. Lee, B.E.; Feinberg, M.; Abraham, J.J.; Murthy, A.R. Congenital malformations in an infant born to a woman treated with fluconazole. Pediatr. Infect. Dis. J. 1992, 11 (12), 1062-1064.
38. King, C.T.; Rogers, P.D.; Cleary, J.D.; Chapman, S.W. Antifungal therapy during pregnancy. Clin. Infect. Dis. 1998, 27 (5), 1151-1160.
39. Sorensen, H.T.; Nielsen, G.L.; Olesen, C.; Larsen, H.; Steffensen, F.H.; Schonheyder, H.C.; Olsen, J.; Czeizel, A.E. Risk of malformations and other outcomes in children exposed to fluconazole in utero. Br. J. Clin. Pharmacol. 1999, 48 (2), 234-238.
40. Rosa, F.W.; Baum, C.; Shaw, M. Pregnancy outcomes after first-trimester vaginitis drug therapy. Obstet. Gynecol. 1987, 69 (5), 751-755.
41. Drugs for vulvovaginal candidiasis. Med. Lett. Drugs Ther. 2001, 43 (1095), 3-4.
42. Czeizel, A.E.; Rockenbauer, M. A lower rate of preterm birth after clotrimazole therapy during pregnancy. Paediatr. Perinat. Epidemiol. 1999, 13 (1), 58-64.